Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sylvant

- PMLiVE

J&J and Pfizer quietly resolve Remicade biosimilar lawsuit

In 2017, Pfizer filed a lawsuit against J&J alleging that the company undertook anticompetitive practices in a bid to protect Remicade

- PMLiVE

J&J, distributors reach $26bn settlement to address the opioid crisis in the US

The proposed agreement would resolve claims of both states and local governments in the US

- PMLiVE

AZ, J&J to research modifications to COVID-19 vaccines over rare blood clot issues

Researchers to explore potential of modifications to vaccine to reduce or remove risk of rare blood clots

- PMLiVE

FDA lists rare neurological condition as potential side effect of J&J’s COVID-19 vaccine

Guillain-Barré syndrome has been reported in 100 people who have received the vaccine in the US

- PMLiVE

J&J’s COVID-19 vaccine shows ‘strong’ activity against Delta variant

Vaccine produces durable immune responses lasting up to eight months

- PMLiVE

Rare diseases: why they can be so difficult to identify

Symptoms shared with more common diagnoses can make it more difficult to spot underlying rare diseases

- PMLiVE

FDA priority review granted for J&J, Legend Biotech’s myeloma CAR T therapy

CAR T therapy demonstrated an overall response rate of 97% in relapsed/refractory multiple myeloma patients after 12.4 months

- PMLiVE

bluebird bio aiming to separate business units by year-end

Biotech company has revealed that its new, separate oncology company will be named 2seventy bio

- PMLiVE

J&J resumes US rollout of single-dose COVID-19 vaccine

CDC and FDA recommended pause be lifted after ‘rigorous review’ of very rare blood clots

- PMLiVE

J&J halts manufacturing of COVID-19 at US plant after FDA warning

Inspection report found facility was “not maintained in a clean and sanitary condition”

- PMLiVE

EMA finds overall benefit-risk ‘remains positive’ for J&J COVID-19 vaccine

Safety committee finds possible link to ‘very rare cases’ of unusual blood blots with low blood platelets

- PMLiVE

Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer

Decision follows mixed results from the phase 3 ACIS study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links